Unveiling the neural network of freezing of gait in Parkinson's disease: A coordinate-based network study

Abstract

Background

Freezing of gait (FoG) is a debilitating symptom in Parkinson's disease (PD), yet its pathophysiological mechanisms remain poorly understood. Several studies have investigated the FoG neuroimaging correlates, with heterogeneous results.

Objective

This study investigated in a large PD cohort whether the disparate neuroimaging findings may converge to a common brain network.

Methods

T1-weighted MRI scans of 500 PD patients (90 with FoG [PD-FoG] and 410 without FoG [PD-nFoG]) were acquired from the Parkinson's Progression Markers Initiative. A voxel-based morphometry (VBM) analysis was conducted to identify clusters of decreased grey matter (GM) in PD-FoG patients. Subsequently, VBM coordinates of significant clusters were used as seed regions to generate connectivity network maps using a large functional normative connectome, and these maps were overlapped to identify regions connected with most VBM clusters.

Results

PD-FoG patients showed GM atrophy in cerebellar lobes, hippocampus, putamen, insula, inferior temporal gyrus and lateral orbitofrontal gyrus compared with PD-nFoG patients. Network analysis revealed that these regions colocalized within a specific brain network focused on midbrain, substantia nigra, subthalamic nucleus, globus pallidus, inferior putamen and dorsal medial cerebellum. These findings were confirmed by using coordinates from previous VBM studies for the network analysis, validating our results.

Conclusions

This study revealed a brain network underlying FoG in PD, reducing the heterogeneity of previous neuroimaging evidence on FoG. These results may represent a significant step forward in the understanding of FoG and may be relevant for optimized targeted neuro-modulatory treatments to reduce FoG in PD patients.

Plain language summary

Freezing of gait (FoG) is a disabling symptom that can occur in Parkinson's disease (PD), where people suddenly find it difficult to start walking or continue moving. This can cause their feet to feel “stuck to the floor” and often happens when turning, walking in tight spaces, or during stressful situations. FoG is typically more commonly observed in the advanced stages of the disease, though not all individuals with PD experience FoG, and can significantly impact daily life and increase the risk of falling. In this study, we used advanced brain imaging techniques to understand what happens in the brain when FoG occurs. We analyzed MRI scans of 480 people with PD, comparing those who experience FoG with those who do not. We found specific areas of the brain where the gray matter was reduced in people with FoG. Using a modern mapping technique, we discovered that these brain areas are part of a connected network involving regions important for movement control, such as the midbrain, globus pallidus, and cerebellum. Our findings suggest that FoG in PD is linked to dysfunction in a brain network, rather than in a single brain region. This understanding may help identify targets for treatments, like deep brain stimulation or other therapies, to improve movement and reduce freezing episodes in people with PD.

Keywords

freezing of gait Parkinson's disease voxel-based morphometry coordinate-based network mapping connectome

Introduction

Freezing of gait (FoG) is a common and debilitating symptom in Parkinson's disease (PD), that contributes to falls and subsequent fractures or other complications, significantly impacting patients’ quality of life.¹ It is characterized by the sudden inability to initiate movement or continue walking, often described as having “a foot glued to the floor”.² These episodes typically occur during turns (especially tight turns in confined spaces), when initiating gait, while walking through narrow passages such as doorways, or when performing other task while walking.^3,4 This phenomenon is particularly prevalent in advanced stages of PD, and affects approximately 50 to 80% of patients.⁵ FoG not only impairs motor function but also significantly reduces quality of life, contributing to greater social isolation, anxiety, and frustration, regardless of disease severity.⁶ Despite its relatively high prevalence in PD patients, the pathophysiological mechanisms underlying FoG remained poorly understood so far, and effective therapeutic strategies are lacking. Current evidence suggests that FoG does not originate from a single brain region, but rather results from impaired communication within brain circuits, particularly involving the mesencephalic locomotor region (MLR).² Other clinical and experimental studies suggested the prominent role of cortical structures, such as the medial fronto-parietal cortex and particularly the supplementary motor area (SMA), with alterations in basal ganglia-SMA connectivity observed in PD patients with FoG.⁷

However, the specific neurobiological substrates contributing to FoG in PD are still subject to debate, and effective therapeutic strategies are lacking. Several structural magnetic resonance imaging (MRI) studies⁸ have revealed grey matter (GM) atrophy in PD patients with FoG, though the specific brain regions implicated often differed across studies, leading to inconsistent and heterogeneous findings. Such discrepancies may result from variations in protocols and analytical methods within voxel-based morphometry (VBM) analyses, or to the small sample size of patients enrolled in most previous studies. Moreover, it is possible that these heterogeneous findings may localize to a common brain network. To test this hypothesis, a technique termed “coordinate-based network mapping” has been recently developed aiming to establish whether different brain regions may share a common functional neural network. This technique leverages large normative connectomes to build connectivity maps for specific seed regions (i.e., previously identified VBM clusters of decreased GM), and thus may allow to identify a common brain network sharing connectivity with multiple seed regions. This approach has been successfully employed to identify a specific network in several neurological diseases, such as Alzheimer's disease,⁹ frontotemporal dementia¹⁰ or migraine,¹¹ and also to identify the neural network associated with specific symptoms in neurodegenerative diseases, including cognitive decline and hallucinations in PD,¹² and alien limb in cortico-basal syndrome.¹³ No study, however, investigated the brain network underlying FoG in PD.

In the current study, we carried out a two-step analysis in a large cohort of around 500 PD patients from the Parkinson's Progression Markers Initiative (PPMI), first identifying VBM clusters of decreased GM in PD patients with FoG, in comparison with those without this symptom, and then performing a modern coordinate-based network mapping analysis on VBM-derived clusters, aiming to investigate whether the identified clusters may converge within a common brain network.

Methods

Study population

Data used in the preparation of this article were obtained on 15 March 2024 from the PPMI database (www.ppmi-info.org/access-data-specimens/download-data), RRID: SCR_006431. For up-to-date information on the study, visit www.ppmi-info.org.

We included 609 PD patients with available volumetric T1-weighted MRI at baseline visit. Age, sex, disease duration, Movement Disorders Society–Unified Parkinson's Disease Rating Scale (MDS–UPDRS), and other relevant clinical information at baseline visit were extracted.

The presence and severity of FoG was scored by summing the item 2.13 “freezing” and item 3.11 “Freezing of gait” scores of the MDS–UPDRS.¹⁴ Scores (item 2.13 + 3.11) of 0 were indicative of no freezing (PD-nFoG, n = 410), while scores greater than or equal to 2 indicated the presence of freezing (PD-FoG, n = 90); scores of 1 were considered ambiguous and these patients were excluded from the analyses (n = 109). Ethics approval was obtained at each site from the local ethics committee, and all participants gave written informed consent.

Preprocessing data

Volumetric T1 images of PD patients were aligned to a DARTEL template space and segmented into GM, white matter (WM), and cerebrospinal fluid (CSF) using Computational Anatomy Toolbox (CAT12).¹⁵ Normalized bias-corrected volumes were checked to ensure that the segmentation and normalization procedures yielded reasonable results. Modulated and normalized GM segments were smoothed using an 8 mm Full Width at Half Maximum (FWHM) Gaussian kernel and checked for sample homogeneity. Patients with higher quartic mean Z-score (above two standard deviations) were discarded as they were identified as outliers (4 PD-FoG and 16 PD-nFoG patients).

VBM analysis

A whole brain VBM analysis was performed using Statistical Parametric Mapping (SPM12) toolbox¹⁶ to identify voxel clusters of decreased GM associated with FoG. We conducted a statistical group-level analysis comparing PD patients with and without FoG using a full factorial model (for a 1 × 2 ANOVA) with age, sex, education, disease duration, MDS-UPDRS-III, Montreal Cognitive Assessment (MoCA), and total intracranial volume (TIV) as covariates. For each group, we defined two sample t-test contrast with [−1, 1, 0] for PD-FoG < PD-nFoG and [1, −1, 0] for PD-FoG > PD-nFoG. Results were assessed at p < 0.05 Family Wise Error (FWE)-corrected for multiple comparisons, as no prior hypotheses were made concerning specific regions of interest. According to the Expected Number of Voxels per Cluster value, only clusters with an extent threshold >59.457 were reported. Coordinates obtained from the VBM analysis comparing PD patient groups with and without FoG were selected as input for the coordinate-based network mapping analysis. First, all VBM-derived coordinates were included; subsequently, we also performed a sensitivity analysis including only the most significant coordinates, automatically selected by SPM12 as described in the Supplemental Material (note to Supplemental Table 1), to test the stability of the coordinate-based network mapping analysis by using a more restrictive set of coordinates, ensuring that the results were not driven by less significant VBM coordinates.

Coordinate-based network mapping

Following VBM analysis, a coordinate-based network mapping approach⁹ was applied to identify a common functional brain network associated with these regions. To this aim, we employed a publicly available functional normative connectome (showing functional relationships across brain regions based on resting state fMRI) to identify functional networks involving the brain structures identified by the structural VBM analysis. Our protocol adopted the same methodology outlined in recent studies.^9,12 In detail, spherical seeds of 4 mm were created centered at each VBM coordinate; we then leveraged the functional normative connectome of 1000 healthy subjects derived from data acquired by the Brain Genomics Superstruct Project (GSP) (https://dataverse.harvard.edu/dataverse/GSP),¹⁷ to generate connectivity network maps from each coordinate-based sphere using the Lead Mapper Connectome toolbox (Supplemental Figure 1).¹⁸ The GSP dataset consists of resting-state fMRI data from young adults (ages 18–35) primarily recruited from the Boston area, who were screened for psychiatric and neurological disorders to ensure a normative sample and underwent high-quality neuroimaging at 3 T.¹⁹ This connectome, which has been widely used in previous studies applying the same technique,^9,11,12 provides a robust reference for coordinate-based network mapping analyses.

Network maps of each coordinate were thresholded at conservative thresholds (T ≥ 5 or T ≥ 7, corresponding to FWE-corrected p < 0.05 and p < 10⁻⁶, respectively) and subsequently overlapped, to identify regions connected to cluster regions derived from the VBM analysis. Connectivity maps shared across more than 75% of VBM coordinates were then identified.

Validation of the results

Finally, to validate our findings, we selected VBM coordinates from previous studies comparing PD patients with and without FoG; these previous studies were selected from those analyzed in a recent systematic review on this topic,⁸ including all studies reporting coordinates of VBM clusters significantly different between PD-FoG and PD-nFoG (n = 4)^7,20–²²;in addition, coordinates extracted from a more recent study not mentioned in the systematic review were also included.²³ None of these previous studies included patients from the PPMI dataset.

As a first step, we performed an activation likelihood estimation (ALE) meta-analysis^24,25 using GingerALE 2.3.6 software (http://brainmap.org/ale). All selected coordinates were converted from Talairach space to MNI space, and a 3D Gaussian probability distribution was generated centered on each individual focus. These distributions were adjusted by the sample size from each study to account for spatial uncertainty surrounding each focus. The distributions were then aggregated across all studies to produce activation likelihood estimate (ALE) maps. Significance was assessed through cluster-level inference, where the observed convergence in ALE values was tested against a null distribution generated from 1000 simulated datasets. Each simulated dataset matched the original in terms of number of foci, studies, and participants but with randomly positioned foci. The cluster-forming threshold was set at FDR-corrected p < 0.001, and the cluster-level inference threshold was at FDR-corrected p < 0.05.⁹ Subsequently, we performed a coordinate-based network mapping approach as described above and compared the findings obtained using VBM coordinates identified in our study with those obtained using VBM coordinates from previous reports.

Results

Demographic and clinical data

Our final cohort included 480 PD patients from the PPMI dataset, stratified into 86 PD patients with FoG and 394 without FoG. No significant differences in age, education, disease duration or MoCA score were found between groups. On the other hand, as expected, PD-FoG patients showed significantly higher scores in MDS-UPDRS II and III sections, indicating greater motor impairment and disability compared to patients without freezing (p < 0.001). Demographic and clinical data for all participants are provided in Table 1.

Table 1.

Demographic and clinical data of patients with Parkinson's disease stratified according to the presence or absence of freezing of gait.

Data	PD-FoG(N = 86)	PD-nFoG(N = 394)	p
Sex (M/F)	59 / 27	223 / 171	0.053^a
Age at examination, y^b	64.6 ± 9.0	62.7 ± 9.7*	0.537^c
Education, y^b	16.4 ± 3.2	15.8 ± 3.1^#	0.145^c
Disease duration, y^b	1.3 ± 1.5	0.98 ± 1.2	0.370^d
MDS UPDRS-I^b	1.94 ± 2.4	1.23 ± 1.7	<0.001^d
MDS UPDRS-II^b	23.77 ± 7.3	9.07 ± 5.9	<0.001^d
MDS UPDRS-III^b	25.8 ± 10.5	21.3 ± 9.7	<0.001^d
H-Y score^b	1.86 ± 0.5	1.64 ± 0.5	<0.001^d
FOG score	2.7 ± 0.7	0	-
MoCA	26.7 ± 2.6	26.9 ± 2.5	0.589^d

PD: Parkinson's disease; FoG: freezing of gait; MDS-UPDRS-III: Movement Disorder Society - Unified Parkinson's Disease Rating Scale- part I, II, III (Motor Examination); H-Y: Hoehn and Yahr; MoCA: Montreal Cognitive Assessment.

Fisher's exact test.

Data are expressed as mean ± standard deviation.

ANOVA or Kruskal-Wallis rank sum test, followed by t-test or Wilcoxon rank sum test with Bonferroni correction.

t-test or Wilcoxon rank sum test.

VBM analysis results between PD patients with and without FoG

VBM analysis revealed 21 coordinates of GM volume reduction in PD-FoG compared with PD-nFoG groups at a threshold of p < 0.05, FWE-corrected, including the bilateral cerebellar lobes, left and right hippocampus, right putamen, left insula, left inferior temporal gyrus, and left lateral orbitofrontal gyrus. A complete list of the VBM coordinates can be found in Supplemental Table 1. No significant clusters of GM volume reduction were found in the opposite comparison (PD-nFoG < PD-FoG groups).

Coordinate-based network mapping

We first conducted a coordinate-based network mapping using all the 21 coordinates obtained from the VBM analysis, applying a threshold of T ≥ 5 and setting the overlap of binarized maps to 75% of clusters (16/21 coordinates [76.2%]) (Supplemental Figure 2). Subsequently, as per sensitivity analysis, the coordinate-based network mapping was repeated using only the 9 most statistically significant coordinates and a more conservative threshold of T ≥ 7 with an overlay of 75% of clusters (7/9 coordinates [77.8%]), and we obtained the same results (Figure 1). Thresholded connectivity network maps from each of these 9 VBM coordinates are shown in Supplemental Figure 1. In both analyses, the overlapping procedure identified a network comprising the midbrain (including substantia nigra), subthalamic nucleus (STN), bilateral globus pallidus, right inferior putamen, temporal poles, and bilateral dorsal medial cerebellum (Figure 2 and Supplemental Figure 3).

Figure 1.

The figure shows the functional coordinate-based network obtained by overlaying at least 75% of thresholded connectivity maps derived using the large normative connectome from the 9 most statistically significant VBM coordinates of GM volume reduction in PD-FoG compared with PD-nFoG from the PPMI cohort.

Figure 2.

The figure shows images from the functional coordinate-based network presented in detail in Figure 1. The colored regions represent the overlay of the masks of the substantia nigra (a) and subthalamic nucleus (b) from the Nigral organization atlas²⁶ and Subthalamic nucleus atlas²⁷ respectively, are overlaid on the coordinate-based network to highlight the presence of the substantia nigra and subthalamic nucleus within our network.

Validation of our findings based on available data from other cohorts

We selected five previous VBM studies^7,20–22 which compared PD-FoG and PD-nFoG patients; this process yielded a total of 18 VBM coordinates we used as input for our analyses. The corresponding brain regions included the midbrain, bilateral thalamus, bilateral putamen, left posterior cingulate, left cuneus and pre-cuneus, left lingual gyrus, left inferior frontal and parietal gyrus, and bilateral cerebellum. A list of the selected studies, with patient cohort information and derived coordinates is shown in Supplemental Table 2. First, we performed a VBM meta-analysis using a standard ALE approach, but this analysis did not reveal any significant clusters. Subsequently, we performed a coordinate-based network mapping approach as described above by using these 18 coordinates derived from previous studies, and we identified a network comprising the midbrain, STN, globus pallidus, inferior putamen, thalamus, Rolandic gyrus and cerebellum (Supplemental Figure 4). This network was very similar to that identified by using VBM coordinates from our patient cohort, as shown in Figure 3, despite using a different set of coordinates. This finding confirmed the involvement of the midbrain, STN, basal ganglia, and dorsal medial cerebellum in FoG, thus validating our results.

Figure 3.

The figure shows a visual representation of the similar findings across the functional network based on the 9 coordinates obtained from the PD-FoG < PD-nFoG from the PPMI cohort and the network based on the coordinates from previous studies. Both networks involved the bilateral dorsal medial cerebellum, midbrain, subthalamic nucleus, globus pallidus and right inferior putamen.

Discussion

This study demonstrated that heterogeneous neuroimaging findings related to FoG in PD, which seem poorly reproducible across studies,²⁸ localized within a common brain network identified using a recent technique known as coordinate-based network mapping.⁹ Notably, this network was identified using data from a large PD cohort from the PPMI dataset and validated using data from previous studies, and encompasses key regions involved in motor control and coordination, including the midbrain, globus pallidus, inferior putamen, STN, and dorsal medial cerebellum.

In the current study, to explore the structural neuroimaging alterations associated with FoG, we performed a VBM analysis in a large international cohort of nearly 500 PD patients from the PPMI, comparing PD patients with and without FoG, well matched for age, sex and disease duration. We identified several significant FWE-corrected clusters of reduced GM volume in PD-FoG patients, including the bilateral cerebellar lobes, bilateral hippocampus, right putamen, left insula, left inferior temporal gyrus and left lateral orbitofrontal gyrus. However, when comparing our results with those from previous smaller VBM studies,^7,20–23 we observed heterogeneous findings, making it challenging to draw definitive conclusions about the specific neural substrates underlying FoG in PD. This is indeed a common issue with VBM studies, which may be due to different methodology (more or less strict correction, variable study design, different covariates), or heterogeneous and small patient groups. To address this issue in neuroimaging, a technique termed “coordinate-based network mapping” has been recently developed aiming to establish whether different brain regions may functionally localize within a common functional neural network. This approach is based on publicly available functional normative connectomes (showing functional relationships across brain regions based on resting state fMRI) and it has successfully been employed to identify the brain networks functionally connected with brain regions identified by VBM analysis. In the current study, we used the VBM coordinates as seed regions to perform coordinate-based network mapping as a more effective approach to elucidate the neural underpinnings of FoG in PD. Unlike traditional VBM or other region-focused analyses, coordinate-based network mapping provides several advantages. First, it allows for a network-level perspective, where distributed patterns of connectivity can be assessed, capturing how multiple brain regions interact as a cohesive unit. This is particularly relevant for complex symptoms like FoG, which likely arise from dysfunctions across an entire network rather than from isolated areas. Furthermore, it enables network analyses bypassing the need for extensive, often unavailable, resting-state fMRI data from large patient cohorts, while still providing network-based insights. It leverages instead normative connectomes, allowing us to map clinical findings onto standardized connectivity templates. Finally, this approach may lead to more robust results, reducing heterogeneity across studies, which is a common issue in the neuroimaging field. In line with this hypothesis, our coordinate-based network approach identified a network of regions functionally connected with most of the coordinates resulting from the VBM comparison between PD patients with and without FoG, and this network was confirmed also when coordinates from previous studies were employed. The involvement of midbrain, globus pallidus, inferior putamen, subthalamic nucleus, and dorsal medial cerebellum was indeed evident in both network analyses, despite a different set of VBM coordinates was employed, demonstrating the existence of a network underlying FoG in PD robustly observed across datasets.

These findings are of relevance since FoG is a debilitating symptom and an essential target for therapeutic intervention.²⁹ To date, however, standard medical treatments for PD such as dopamine replacement therapy has shown limited benefit.⁴ For this reason, invasive and non-invasive neuromodulation techniques are increasingly being utilized, making it of pivotal importance to get a precise understanding of the involved network and the brain structures to target for effectively addressing this symptom.³⁰ The structures identified by our network analysis are biologically plausible and well in line with previous findings on FoG in PD patients. For example, the cerebellar regions identified in the current study perfectly overlap with a previous important lesion-based network mapping study,³¹ which also identified the dorsal medial region of the cerebellum as a critical player in FoG. The authors found that coordinates of neoplastic or cerebrovascular lesions in various brain areas producing FoG were all functionally connected to a focal region in the dorsal medial cerebellum, a part of the cerebellar locomotor region (CLR), which is implicated in locomotion and is closely linked to the leg area of the primary motor cortex (M1). Our findings do corroborate the involvement of this cerebellar subregion in FoG, and suggest that this may be symptom-specific rather than associated with a particular disease, given that this brain area seems related to FoG in PD patients in our study and to FoG due to brain lesions in the previous report. This overlap between lesion network mapping and coordinate-based network mapping highlights a potential therapeutic target within the cerebellum for alleviating FoG symptoms, needing further research. While direct cerebellar stimulation through invasive approaches presents practical and tolerability challenges, recent studies³² suggested that non-invasive cerebellar stimulation (NICS) may offer in the future a feasible alternative to improve motor symptoms in PD. Specifically, NICS has been explored as a promising approach to modulate motor networks in PD patients, with preliminary findings indicating its potential to improve gait and motor symptoms.³³ Future studies should explore the potential of NICS for treating FoG potentially in combination with motor-cognitive training programs are warranted. In addition to the cerebellum, our coordinate-based network identified without any a-priori hypothesis the globus pallidus and the STN, which have been used as stimulation targets for deep brain stimulation (DBS) in recent studies attempting to treat FoG in PD patients.^28,34–36 Some authors reported that DBS targeting the STN can alleviate FoG,^37,38 and the improvement was related to stimulation of STN portions structurally connected to motor areas and globus pallidus.³⁹ Moreover, in another study, DBS was more effective when targeted both the STN and substantia nigra pars reticulata (SNr), which was also identified by our network analysis and is functionally associated with globus pallidus internus, reinforcing the hypothesis of a network dysfunction involving these regions as pathophysiological basis of FoG in PD patients.³⁵ Our study has several strengths that enhance the validity and relevance of our findings. First, this is the largest neuroimaging study on FoG and we included a large, multicentric PD cohort, thus enhancing the generalizability of our findings. Second, PD groups with and without FoG were well matched for demographic variables and for disease duration and cognitive scores, which were also included as covariates, thus minimizing the influence of confounding factors in the VBM analysis. Third, we validated our coordinate-based network results by using data from two independent sources, namely the PPMI cohort included in the current study and available data from the existing “non-PPMI” literature, overcoming VBM heterogeneity and allowing us to draw more reliable conclusions about the neural substrates associated with FoG across diverse patient populations. While this study provides valuable insights into the neuroimaging findings related to a FoG network in PD, some limitations must be acknowledged. First, the study primarily involved patients with early-stage PD, and the observed FoG symptoms were relatively mild. Future studies are needed to better explore the neuroimaging correlates of FoG severity in more advanced stages of the disease. Second, our study did not include a healthy control group. We primarily focused on a specific symptom (FoG), and we thus compared PD patients with and without FoG, rather than exploring the broader anatomical bases of PD. Future research may compare PD versus HC to investigate the presence of a PD-specific network in comparison with healthy controls and expand current knowledge on this topic. Third, our approach utilized a normative connectome to link heterogeneous neuroimaging findings, similar to prior works.^40,41 Although this methodology is well established, it may be hypothesized that using a connectome derived from PD patients could yield more informative results in linking neuroimaging findings specifically within this population. However, connectomes from patients are usually created on a small number of subjects, potentially bringing uncertainty into the results,⁴² and available data suggest that employing such connectomes has minimal impact on network mapping outcomes.⁴³

In conclusion, this study represents a significant step forward in unraveling the brain network related to FoG in PD. By leveraging coordinate-based network mapping, this work unified previously heterogeneous neuroimaging findings into a cohesive brain network, identifying key regions such as the midbrain, subthalamic nucleus, inferior putamen, globus pallidus, and dorsal medial cerebellar lobules, that collectively contribute to FoG. This network-oriented approach highlights potential therapeutic targets for interventions like DBS, suggesting a path forward for refining treatments to alleviate this disabling symptom, ultimately improving patient outcomes and quality of life.

Supplemental Material

sj-docx-1-pkn-10.1177_1877718X251348669 - Supplemental material for Unveiling the neural network of freezing of gait in Parkinson's disease: A coordinate-based network study

Supplemental material, sj-docx-1-pkn-10.1177_1877718X251348669 for Unveiling the neural network of freezing of gait in Parkinson's disease: A coordinate-based network study by Chiara Camastra, Antonio Augimeri, Aldo Quattrone and Andrea Quattrone in Journal of Parkinson's Disease

Footnotes

Acknowledgements

PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.

ORCID iDs

Chiara Camastra

Antonio Augimeri

Aldo Quattrone

Andrea Quattrone

Ethical considerations

Ethics approval was obtained at each site from the local ethics committee, and all participants gave written informed consent.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data availability statement

The data supporting the findings of this study are openly available in the Image and Data Archive (IDA) at .

Supplemental material

Supplemental material for this article is available online.

References

Giladi

Treves

Simon

, et al. Freezing of gait in patients with advanced Parkinson’s disease. J Neural Transm (Vienna) 2001; 108: 53–61.

Nutt

Bloem

Giladi

, et al. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol 2011; 10: 734–744.

Okuma

. Practical approach to freezing of gait in Parkinson’s disease. Pract Neurol 2014; 14: 222–230.

Nonnekes

Snijders

Nutt

, et al. Freezing of gait: a practical approach to management. Lancet Neurol 2015; 14: 768–778.

Herman

Rosenberg-Katz

Jacob

, et al.

Gray matter atrophy and freezing of gait in Parkinson’s disease: is the evidence black-on-white?

Mov Disord 2014; 29: 134–139.

Walton

Shine

Hall

, et al. The major impact of freezing of gait on quality of life in Parkinson’s disease. J Neurol 2015; 262: 108–115.

Jha

Jhunjhunwala

Sankara

, et al. Neuropsychological and imaging profile of patients with Parkinson’s disease and freezing of gait. Parkinsonism Relat Disord 2015; 21: 1184–1190.

Bharti

Suppa

Tommasin

, et al. Neuroimaging advances in Parkinson’s disease with freezing of gait: a systematic review. Neuroimage Clin 2019; 24: 102059.

Darby

Joutsa

Fox

. Network localization of heterogeneous neuroimaging findings. Brain 2019; 142: 70–79.

10.

Chu

Jiang

, et al. Atrophy network mapping of clinical subtypes and main symptoms in frontotemporal dementia. Brain 2024; 147: 3048–3058.

11.

Burke

Joutsa

Cohen

, et al. Mapping migraine to a common brain network. Brain 2020; 143: 541–553.

12.

Weil

Hsu

Darby

, et al. Neuroimaging in Parkinson’s disease dementia: connecting the dots. Brain Commun 2019; 1: fcz006.

13.

Tetreault

Phan

Petersen

, et al. Network localization of alien limb in patients with corticobasal syndrome. Ann Neurol 2020; 88: 1118–1131.

14.

Chen

, et al. Freezing of gait is a risk factor for cognitive decline in Parkinson’s disease. J Neurol 2023; 270: 466–476.

15.

Gaser

Dahnke

Thompson

, et al. CAT: a computational anatomy toolbox for the analysis of structural MRI data. GigaScience 2024; 13: giae049.

16.

Friston

Ashburner

Heather

. Statistical parametric mapping. In: Kotter

(eds) Neuroscience databases: a practical guide. Boston, MA: Springer, 2003, pp.237–250.

17.

Yeo

BTT

Krienen

Sepulcre

, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol 2011; 106: 1125–1165.

18.

Horn

Kühn

. Lead-DBS: a toolbox for deep brain stimulation electrode localizations and visualizations. Neuroimage 2015; 107: 127–135.

19.

Holmes

Hollinshead

O’Keefe

, et al. Brain genomics superstruct project initial data release with structural, functional, and behavioral measures. Sci Data 2015; 2: 150031.

20.

Tessitore

Amboni

Cirillo

, et al. Regional gray matter atrophy in patients with Parkinson disease and freezing of gait. AJNR Am J Neuroradiol 2012; 33: 1804–1809.

21.

Kostic

Agosta

Pievani

, et al. Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. Neurology 2012; 78: 409–416.

22.

Rubino

Assogna

Piras

, et al.

Does a volume reduction of the parietal lobe contribute to freezing of gait in Parkinson’s disease?

Parkinsonism Relat Disord 2014; 20: 1101–1103.

23.

Droby

Pelosin

Putzolu

, et al. A multimodal imaging approach demonstrates reduced midbrain functional network connectivity is associated with freezing of gait in Parkinson’s disease. Front Neurol 2021; 12: 583593.

24.

Eickhoff

Laird

Grefkes

, et al. Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum Brain Mapp 2009; 30: 2907–2926.

25.

Eickhoff

Laird

Fox

, et al. Implementation errors in the GingerALE software: description and recommendations. Hum Brain Mapp 2017; 38: 7–11.

26.

Zhang

Larcher

KMH

Misic

, et al. Anatomical and functional organization of the human substantia nigra and its connections. eLife 2017; 6: e26653.

27.

Forstmann

Keuken

Jahfari

, et al. Cortico subthalamic white matter tract strength predicts interindividual efficacy in stopping a motor response. Neuroimage 2012; 60: 370–375.

28.

Rahimpour

Gaztanaga

Yadav

, et al. Freezing of gait in Parkinson’s disease: invasive and noninvasive neuromodulation. Neuromodulation 2021; 24: 829–842.

29.

Falla

Cossu

Di Fonzo

. Freezing of gait: overview on etiology, treatment, and future directions. Neurol Sci 2022; 43: 1627–1639.

30.

Martinez-Nunez

Justich

Okun

, et al. Emerging therapies for neuromodulation in Parkinson’s disease. Neurotherapeutics 2024; 21: e00310.

31.

Fasano

Laganiere

Lam

, et al. Lesions causing freezing of gait localize to a cerebellar functional network. Ann Neurol 2017; 81: 129–141.

32.

Billeri

Naro

. A narrative review on non-invasive stimulation of the cerebellum in neurological diseases. Neurol Sci 2021; 42: 2191–2209.

33.

Potvin-Desrochers

Paquette

. Potential non-invasive brain stimulation targets to alleviate freezing of gait in Parkinson’s disease. Neuroscience 2021; 468: 366–376.

34.

Fan

Guo

Jiang

, et al. Optimal subthalamic stimulation sites and related networks for freezing of gait in Parkinson’s disease. Brain Commun 2023; 5: fcad238.

35.

Popova

Messé

Gulberti

, et al. The effect of deep brain stimulation on cortico-subcortical networks in Parkinson’s disease patients with freezing of gait: exhaustive exploration of a basic model. Netw Neurosci 2024; 8: 926–945.

36.

Barbe

Tonder

Krack

, et al. Deep brain stimulation for freezing of gait in Parkinson’s disease with early motor complications. Mov Disord 2020; 35: 82–90.

37.

Hirata

Hattori

Kina

, et al. Striatal dopamine denervation impairs gait automaticity in drug-naïve Parkinson’s disease patients. Mov Disord 2020; 35: 1037–1045.

38.

Vercruysse

Vandenberghe

Münks

, et al. Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson’s disease: a prospective controlled study. J Neurol Neurosurg Psychiatry 2014; 85: 871–877.

39.

Strelow

Baldermann

Dembek

, et al. Structural connectivity of subthalamic nucleus stimulation for improving freezing of gait. J Parkinsons Dis 2022; 12: 1251–1267.

40.

Darby

Joutsa

Burke

, et al. Lesion network localization of free will. Proc Natl Acad Sci U S A 2018; 115: 10792–10797.

41.

Fox

. Mapping symptoms to brain networks with the human connectome. N Engl J Med 2018; 379: 2237–2245.

42.

Horn

Reich

Vorwerk

, et al. Connectivity predicts deep brain stimulation outcome in Parkinson disease. Ann Neurol 2017; 82: 67–78.

43.

Cohen

Fox

. Reply: the influence of sample size and arbitrary statistical thresholds in lesion-network mapping. Brain 2020; 143: 41.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

8.42 MB